GlassScriptPhysician profile
Dana Roberts
NPI 1457706913
$2,675.60
in general payments reported to CMS, 2019-2025
23 companies · $69.44 in 2025
The $69.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $721 · 2023: $688 · 2024: $529 · 2025: $69.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.73 | 2021-2025 | |
| Novo Nordisk INC | $206.75 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Janssen Pharmaceuticals, INC | $187.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.36 | 2021-2023 | Trintellix |
| Pfizer INC. | $142.61 | 2023-2024 | |
| Glaxosmithkline, LLC. | $99.39 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $89.19 | 2021-2022 | |
| Lilly USA, LLC | $66.91 | 2021-2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $54.23 | 2022 | |
| Sumitomo Pharma America, INC. | $50.29 | 2023 | Gemtesa |
| Astellas Pharma US INC | $44.70 | 2021-2022 | |
| Amgen INC. | $43.86 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $41.00 | 2021-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $40.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.45 | 2021-2024 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.41 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2022 | |
| Daiichi Sankyo INC. | $15.15 | 2021 | |
| Nabriva Therapeutics, Plc | $14.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.65 | 2021 | |
| Esperion Therapeutics, INC. | $12.91 | 2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.